TY - JOUR
T1 - CXCR4 Expression as a Prognostic Biomarker in Soft Tissue Sarcomas
AU - Virgili, Anna
AU - Salazar, Juliana
AU - Gallardo, Alberto
AU - López-Pousa, Antonio
AU - Terés, Raúl
AU - Bagué Rosell, Sílvia
AU - Fumagalli, Caterina
AU - Mangues, Ramon
AU - Alba-Castellón, Lorena
AU - Unzueta Elorza, Ugutz
AU - Casanova Rigat, Isolda
AU - Sebio, Ana
N1 - Publisher Copyright:
© 2024 by the authors.
PY - 2024/6
Y1 - 2024/6
N2 - Poor long-term survival in localized high-risk soft tissue sarcomas (STSs) of the extremities and trunk highlights the need to identify new prognostic factors. CXCR4 is a chemokine receptor involved in tumor progression, angiogenesis, and metastasis. The aim of this study was to evaluate the association between CXCR4 expression in tumor tissue and survival in STSs patients treated with neoadjuvant therapy. CXCR4 expression was retrospectively determined by immunohistochemical analysis in serial specimens including initial biopsies, tumors post-neoadjuvant treatment, and tumors after relapse. We found that a positive cytoplasmatic expression of CXCR4 in tumors after neoadjuvant treatment was a predictor of poor recurrence-free survival (RFS) (p = 0.003) and overall survival (p = 0.019) in synovial sarcomas. We also found that positive nuclear CXCR4 expression in the initial biopsies was associated with poor RFS (p = 0.022) in undifferentiated pleomorphic sarcomas. In conclusion, our study adds to the evidence that CXCR4 expression in tumor tissue is a promising prognostic factor for STSs.
AB - Poor long-term survival in localized high-risk soft tissue sarcomas (STSs) of the extremities and trunk highlights the need to identify new prognostic factors. CXCR4 is a chemokine receptor involved in tumor progression, angiogenesis, and metastasis. The aim of this study was to evaluate the association between CXCR4 expression in tumor tissue and survival in STSs patients treated with neoadjuvant therapy. CXCR4 expression was retrospectively determined by immunohistochemical analysis in serial specimens including initial biopsies, tumors post-neoadjuvant treatment, and tumors after relapse. We found that a positive cytoplasmatic expression of CXCR4 in tumors after neoadjuvant treatment was a predictor of poor recurrence-free survival (RFS) (p = 0.003) and overall survival (p = 0.019) in synovial sarcomas. We also found that positive nuclear CXCR4 expression in the initial biopsies was associated with poor RFS (p = 0.022) in undifferentiated pleomorphic sarcomas. In conclusion, our study adds to the evidence that CXCR4 expression in tumor tissue is a promising prognostic factor for STSs.
KW - CXCR4
KW - Prognostic factor
KW - Soft tissue sarcomas
KW - Synovial sarcomas
KW - Undifferentiated pleomorphic sarcomas
KW - undifferentiated pleomorphic sarcomas
KW - soft tissue sarcomas
KW - synovial sarcomas
KW - prognostic factor
UR - http://www.scopus.com/inward/record.url?scp=85195925678&partnerID=8YFLogxK
UR - https://www.mendeley.com/catalogue/6656298e-9bd3-329c-971b-a3c3db4b53cb/
U2 - 10.3390/diagnostics14111195
DO - 10.3390/diagnostics14111195
M3 - Article
C2 - 38893721
SN - 2075-4418
VL - 14
JO - Diagnostics
JF - Diagnostics
IS - 11
M1 - 1195
ER -